FDA NDC Directory · JSON-LD · Markdown

Synagis

NDC 66658-230 · HUMAN PRESCRIPTION DRUG · INJECTION, SOLUTION

Generic namepalivizumab
Labeler / ManufacturerSwedish Orphan Biovitrum AB (publ)
Marketing categoryBiologic License Application · App BLA103770
Dosage form / routeINJECTION, SOLUTION · INTRAMUSCULAR
Active ingredientsPALIVIZUMAB (50 mg/.5mL)
Marketing started19991209
Marketing ended20260930
Package count1

External sources

Source: openFDA. Public-domain (CC0).